Global Dyslipidemia Drugs Market 2017-2021 - Product Image

Global Dyslipidemia Drugs Market 2017-2021

  • ID: 4143919
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • AstraZeneca
  • Cerenis
  • CKD Bio
  • Eli Lilly
  • JW Pharmaceuticals
  • MORE
About Dyslipidemia Drugs

Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.

The analysts forecast the global dyslipidemia drugs market to grow at a CAGR of 5.27% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global dyslipidemia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Dyslipidemia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarin Corporation
- Amgen
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis
- Cipla
- CJ HealthCare
- CKD Bio
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Eli Lilly
- Esperion Therapeutics
- GlaxoSmithKline
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Lupin Pharmaceuticals

Market drivers
- Change in ATP guidelines for management of hypercholesterolemia.
- For a full, detailed list, view the full report

Market challenges
- Drawbacks associated with current therapies.
- For a full, detailed list, view the full report

Market trends
- Increased uptake of OTC drugs.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • AstraZeneca
  • Cerenis
  • CKD Bio
  • Eli Lilly
  • JW Pharmaceuticals
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of dyslipidemia

PART 06: Pipeline analysis

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by drug class
  • Statins
  • Cholesterol absorption inhibitors
  • Dyslipidemia injectables
  • Others
PART 09: Geographical segmentation
  • Dyslipidemia drugs market in Americas
  • Dyslipidemia drugs market in EMEA
  • Dyslipidemia drugs market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Increasing use of statins
  • Combination therapies
  • Increased uptake of OTC drugs
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Key customer segments
Exhibit 02: Overview of phase III pipeline molecules in global dyslipidemia drugs market
Exhibit 03: Pipeline analysis
Exhibit 04: Global dyslipidemia drugs market snapshot 2016
Exhibit 05: Global dyslipidemia drugs market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Global dyslipidemia drugs market by drug class
Exhibit 08: Global statin market 2016-2021 ($ millions)
Exhibit 09: Global cholesterol absorption inhibitors market 2016-2021 ($ millions)
Exhibit 10: Global dyslipidemia injectables market 2016-2021 ($ millions)
Exhibit 11: Global dyslipidemia drugs market by geography 2016 and 2021
Exhibit 12: Dyslipidemia drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Dyslipidemia drugs market in Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Dyslipidemia drugs market in the EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario in APAC
Exhibit 18: Dyslipidemia drugs market in APAC 2016-2021 ($ millions)
Exhibit 19: Population aged 60 years and over: World and developed and developing regions (millions)
Exhibit 20: Impact of drivers
Exhibit 21: Impact of challenges
Exhibit 22: Competitive structure analysis of global dyslipidemia drugs market 2016
Exhibit 23: Competitive analysis of global dyslipidemia drugs market 2016
Exhibit 24: Market penetration of various players in global dyslipidemia drugs market 2016
Exhibit 25: Aegerion Pharmaceuticals: Key highlights
Exhibit 26: Aegerion Pharmaceuticals: Strength assessment
Exhibit 27: Aegerion Pharmaceuticals: Strategy assessment
Exhibit 28: Aegerion Pharmaceuticals: Opportunity assessment
Exhibit 29: AstraZeneca: Key highlights
Exhibit 30: AstraZeneca: Strength assessment
Exhibit 31: AstraZeneca: Strategy assessment
Exhibit 32: AstraZeneca: Opportunity assessment
Exhibit 33: Merck: Key highlights
Exhibit 34: Merck: Strength assessment
Exhibit 35: Merck: Strategy assessment
Exhibit 36: Merck: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Exhibit 41: Sanofi: Key highlights
Exhibit 42: Sanofi: Strength assessment
Exhibit 43: Sanofi: Strategy assessment
Exhibit 44: Sanofi: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • AstraZeneca
  • Cerenis
  • CKD Bio
  • Eli Lilly
  • JW Pharmaceuticals
  • MORE
New Report Released: – Global Dyslipidemia Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global dyslipidemia drugs market: AstraZeneca, Merck, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis, Cipla, CJ HealthCare, CKD Bio, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, JW Pharmaceuticals, Kadmon Pharmaceuticals, and Lupin Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “One trend in market is increasing use of statins. Statins dominate the global dyslipidemia drugs market. Statins are reported to be the most effective among all dyslipidemia drugs in lowering the risk of heart attacks. The ATP IV guidelines, which are based on data from randomized controlled trials, strongly recommend the use of statins to manage atherosclerotic CVD. The ATP IV guidelines have identified four treatment groups for statins and have recommended treatment based on intensity groups. For instance, it recommends the use of high-intensity statins in individuals with established atherosclerotic CVD. The other two intensity groups include moderate-intensity statin therapy and low-intensity statin therapy. Furthermore, the ATP IV panel found no evidence in support of using non-statin cholesterol-lowering drugs in individuals with statin intolerance or as a component of combination therapy. Moreover, the current ATP guidelines might not support the use of non-statin therapy in statin-tolerant patients.”

According to the report, one driver in market is increasing risk of CVDs. Elevated levels of cholesterol in the blood lead to the deposition of cholesterol in the arterial walls, which results in atherosclerosis, hardening and narrowing the arteries. The resultant narrowing of blood vessels decreases the blood flow to the heart muscles, causing a heart attack. High cholesterol levels account for nearly one-third of all ischemic heart diseases and hence, remain a significant cause of ischemic heart diseases and strokes in developed and developing countries such as India and China. Data estimates suggest that among men aged 40 years and over, a 10% decrease in serum cholesterol levels reduces the risk of heart disease by 50% within five years. Hence, cardiovascular risk management guidelines by authorities such as the American College of Cardiology and American Heart Association consider reducing blood cholesterol an important factor in reducing cardiovascular risk. As cholesterol disorder is one of the major causes for CVDs, patients try to strictly adhere to cholesterol maintaining drugs to avoid the occurrence of CVD. This preventive approach toward the occurrence of CVDs will further boost the sales of cholesterol controlling agents.

Further, the report states that one challenge in market is drawbacks associated with current therapies. Statins are prescribed drugs for lowering LDL-C levels and constitute the first line of therapy for hypercholesterolemia. However, long-term administration and the muscle-related side effects of statins lead to poor patient compliance. Doubling the dose of statins might increase drug toxicity with a negligible increase in LDL-lowering effects. Furthermore, in February 2012, the FDA announced that statins could be associated with side effects such as cognitive effects and hyperglycemia. Bile acid sequestrates lead to side effects related to the gastrointestinal tract. Niacin-based formulations are generally associated with flushing and hepatotoxicity. Fibrates are associated with an increased risk of cholesterol gallstones and side effects related to the gastrointestinal tract. Thus, there is a high demand for lipid-lowering drugs with a good safety profile.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Alnylam Pharmaceuticals
  • Amarin Corporation
  • Amgen
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Eli Lilly
  • Esperion Therapeutics
  • GlaxoSmithKline
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Lupin Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll